HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dolichos biflorus agglutinin binding in hereditary bowel cancer.

Abstract
Dolichos biflorus agglutinin (DBA) binds specifically to N-acetylgalactosamine (GalNAc), one of the 5 sugars contributing to the oligosaccharide component of human colorectal goblet cell mucin. DBA binds to goblet cells of the upper crypt and surface epithelium within the proximal colon and to the majority of goblet cells of the distal large bowel. DBA therefore serves as a marker of colorectal goblet cell differentiation with a distinct proximal to distal gradient effect. Previous reports indicate significant loss of DBA reactivity within morphologically normal colorectal mucosa derived from at-risk members of hereditary non-polyposis colorectal cancer (HNPCC) families. This finding could not be confirmed in the present study. Reduced binding was a relatively consistent finding in transitional mucosa, hyperplastic polyps and carcinoma, with adenomas displaying a more varied pattern of loss. Reduced binding by DBA may be explained by several mechanisms and may not necessarily reflect loss of GalNAc. The concept that lectins can be used to identify stepwise changes that occur during neoplastic evolution should not be accepted uncritically.
AuthorsJ R Jass, L J Allison, S M Stewart, M R Lane
JournalPathology (Pathology) Vol. 26 Issue 2 Pg. 110-4 (Apr 1994) ISSN: 0031-3025 [Print] England
PMID8090579 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Lectins
  • Plant Lectins
  • dolichos biflorus agglutinin
Topics
  • Adenomatous Polyposis Coli (metabolism, pathology)
  • Colon (metabolism, pathology)
  • Colorectal Neoplasms, Hereditary Nonpolyposis (metabolism, pathology)
  • Humans
  • Intestinal Mucosa (metabolism, pathology)
  • Intestine, Large (metabolism, pathology)
  • Lectins (metabolism)
  • Plant Lectins
  • Protein Binding
  • Rectum (metabolism, pathology)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: